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Abstract: The ability to probe diseases at the genomic level has improved our understanding 
and enhanced the treatment of breast cancer. One important finding relates to the HER2 
oncogene which encodes a novel transmembrane receptor that, when overexpressed, appears to 
confer growth and survival advantages to breast tumor cells. This fortuitous discovery enabled 
researchers to develop agents which could inhibit receptor-mediated tumor cell signaling. 
Numerous clinical trials of such agents have demonstrated improved outcomes in patients 
with HER2-positive breast cancer. Nonetheless, not all tumors respond to therapy targeting the 
receptor, while relapses occur after an initial response to treatment. This paper provides a historical 
and current perspective of the treatment of patients with HER2-positive breast cancer.
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HER introduction
Creation and completion of ground breaking clinical trials have led to improved 
outcomes in patients with breast cancer, especially those with early-stage disease. 
Supported by compelling evidence collected over the past 40 years,1–4 optimal 
management of patients with primary operable breast cancer is based on a paradigm 
of minimal, rather than maximal, therapeutic intervention. Surgical lumpectomy, for 
example, obviates, or at least attenuates, some of the anatomical and psychological 
issues associated with mastectomy;1 sentinel node biopsy may circumvent the need 
for, and preserves arm function better than, complete (axillary) nodal dissection;5,6 and 
endocrine therapy alone improves survival in patients with early, hormone-responsive 
breast cancers.7 The latter intervention also embraces the concept that treatment may 
depend, in part, on identification of unique tumor characteristics. Hence, the ability 
to probe the disease at the molecular level not only improved our understanding of 
how estrogens mediated malignant tumor growth but also enhanced our knowledge 
base, upon which the fertile idea of the estrogen receptor (ER) as a tumor target was 
conceived.8 A second tumor target surfaced with identification of a novel oncogene 
that encodes the human epidermal growth factor receptor 2 (HER2) protein.
Even though the discoveries of the ER and HER2 are separated by 2 decades, 
the receptors appear to be linked in a number of ways. First, both are important 
breast cancer targets. In fact, the lessons learned with the selective estrogen receptor 
modulator tamoxifen have been wisely applied to the development of trastuzumab, 
a humanized monoclonal antibody that recognizes and binds HER2; and while International Journal of Women’s Health 2009:1 156
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not always appreciated, the concept of “targeted therapy” 
in oncology really began with tamoxifen. Second, both 
receptors are predictive markers in that high-level expres-
sion of ER and HER2 is associated with (though not 
absolute) response to therapies directed against their respec-
tive targets. The 2 receptors are also prognostic factors; 
independent of treatment, expression of ER (ie, ER-positive 
tumors) and absence of HER2 (ie, HER2-negative tumors, 
except triple negative) correlates with a relatively good 
prognosis for patients with early breast cancer. Third, and 
perhaps the most intriguing relationship, is the cross-talk 
that allegedly occurs between the 2 receptors, a form of 
communication which may contribute to the development 
of some tamoxifen-resistant tumor cells.9,10 Also interesting 
is the finding that despite disease progression, the receptors 
appear to remain viable targets, which suggests that (at least 
for a subset of patients) signaling through the receptors 
continue to mediate tumor cell growth and survival.11–13 
Nevertheless, the uncertainty of the mechanisms by 
which tumors become resistant has negative implications, 
especially for developing new agents against endocrine- or 
HER2-refractory disease.
The goal of this paper is to provide an insight on the 
role and impact of HER2 in breast cancer. As such, events 
culminating with the discovery of the receptor and devel-
opment of agents targeting the receptor are reconstructed; 
clinical trial results leading to drug approval are reviewed; 
safety data that may soften the benefit to risk ratio are 
readdressed; and the mechanisms and implications of drug-
resistance are reassessed. In order to enhance reader appre-
ciation of the complex processes underlying HER2-mediated 
breast tumor growth, a brief description of the receptor is 
discussed initially.
HER family
Originally designated as “neu” because of its association with 
rat neuroblastoma cell lines, the oncogene was believed to be 
related to an oncogene found in avian erythroblastosis viruses 
(v-ErbB) that encodes epidermal growth factor receptor 
(EGFR).14 The substantial homology between EGFR and the 
neu oncoprotein was also the basis from which HER (human 
EGFR-related) 2 derived its name.15 HER2/neu is a member 
of the ErbB family of receptor tyrosine kinases, a homologous 
group that also includes HER1 (EGFR), HER3, and HER4. 
Structurally, all members have a short transmembrane that 
connects the extracellular portion to the intracellular catalytic 
kinase and regulatory domains (Figure  1).16 Ligand binding 
initiates a sequence of events including receptor dimerization 
and kinase phosphorylation, which trigger intracellular 
signal transduction. The ultimate cellular response depends 
on recruitment and activation of various protein kinases 
located downstream of the receptor. Signaling, however, is 
a phenomenally complex process, more of which will be 
discussed later. In addition, the authors direct readers to 
excellent reviews of this topic.17–19
Physiologically, the ErbB family has long been known 
to contribute to the development of a number of important 
organs and tissue systems.20,21 Although not restricted 
to mammary tissue, studies of HER isoforms suggest 
each receptor has a different function in normal gland 
development. While HER2 promotes lobuloalveolar differ-
entiation and lactation, HER1 contributes to ductal growth.22 
Paradoxically, compelling evidence linking these receptors 
to human neoplasia, including breast cancer, had been 
reported over 2 decades ago.15,23,24 For instance, high levels 
of the HER2 and EGFR have been found in breast cancer 
(as well as a number of other solid tumors).25 In addition, 
amplification of the HER2-oncogene or overexpression of the 
oncoprotein has been shown to convey tumor cell growth and 
survival advantages.26 Although overexpression is paramount 
to the transformed state, it remains unclear whether HER2 
aberrations arise very early (ie, hyperplasia) or much later 
(ie, neoplasia) in the tumorigenic process. The determination 
of when this functional abnormality occurs may be crucial as 
earlier detection may improve the prognosis of a significant 
number of patients.
HER presence
Amplified (gene) or overexpressed (receptor) in approximately 
20% to 25% of breast cancers, HER2-positivity is associated 
with a number of adverse tumor characteristics involving 
size, nuclear grade, S-phase fraction, and ploidy.27 Perhaps 
more important is the clinical correlation between receptor-
positive tumors and higher risks of relapse, shorter time 
to disease progression, and poorer overall survival.28 The 
significance of the genomic abnormality was important 
because positive correlation between HER2 gene amplifica-
tion and breast cancer formed the basis for the development 
of a useful clinical test29,30 as well as an effective therapeutic 
strategy.31
It is conceivable that amplification and/or overex-
pression of the three other HER-related family members 
may also influence the clinical course and outcomes of 
HER2-positive breast cancer. For example, data linking 
co-expressed EGFR with increased HER2 signaling activity 
and poorer overall prognosis have been published.32,33 International Journal of Women’s Health 2009:1 157
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There is also striking evidence for the negative impact of 
altered HER3 on disease outcome in patients with breast 
cancer.34 Furthermore, others have reported that any 
combination of EGFR, HER2, and HER3 was associated 
with significantly reduced disease-specific survival.35 
In contrast, expression of HER4 has frequently been related 
to a more favorable breast cancer prognosis.36 Because of 
their retrospective nature, the clinical significance of the 
co-expression data is still uncertain. This conclusion is 
supported by two findings. First, while information related 
to HER2 overexpression is usually remarkably similar 
(ie, 23% to 27%), analysis of EGFR (16% to 36%), HER3 
(18% to 26%), and HER4 (12% to 82%) overexpression 
indicates more variabilty.36–38 Second, expression of these 
receptors may, interestingly, increase or decrease during 
the course of the disease.39 Nonetheless, prospective quan-
tification of these receptors may provide clinically relevant 
information related to disease outcome.
HER therapy
Even though only two agents (that target the receptor) have 
received FDA approval for use in patients with HER2-positive 
breast cancer, their impact, especially trastuzumab 
(HerceptinTM; Genentech, Inc.), have been substantial. 
Several phase III and II clinical trials (discussed later) with 
lapatinib (TykerbTM; GlaxoSmithKline) suggest that the 
newer agent is at least as active as trastuzumab. What may 
also be learned about these 2 agents is whether attenuation 
of receptor signaling (and hence, antitumor effect and cross-
resistance) differs with respect to the external or internal 
drug-binding sites.
Trastuzumab
Trastuzumab is a recombinant humanized monoclonal 
antibody that recognizes and binds with high affinity to 
an epitope on the extracellular domain of HER2. Notably, 
trastuzumab does not “compete” with an endogenous ligand 
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Figure 1 Schema of the HER family signaling pathways. The linear pathway whereby each component merely functions as a relay switch is grossly oversimplified.   The ultimate 
cellular response is dependent on a diverse array of signals, which is mediated by receptor cross-talk, feedback loops, and counter-regulatory activities. Following ligand 
binding, the receptor dimerizes and is then phosphorylated.   The Ras pathway is especially complex as the kinase must undergo post-translational modification before 
it can be activated. Phosphorylated Her2 is linked to the ras signal transduction pathway by binding to 2 adaptor molecules (Shc) and growth-factor receptor bound 
protein 2 (GrB2). GrB2 forms a complex with son of sevenless (SoS) which is recruited to the plasma membrane leading to activation of ras. extracellular signals are 
propagated from cell surface to nucleus through dynamic interactions with components located downstream of the receptor including PI3K, Akt, and nuclear factor 
(NF-κβ).   Akt blocks apoptosis by antagonizing a proapoptotic member of the Bcl-2 family, Bad, or upregulating Bcl-XL, an anti-apoptotic member of the Bcl-2 family. Akt 
can also effect angiogenesis via mTor-induced hypoxia inducible factor-1 alpha (HIF-1α) activation. Other downstream effectors of the ras signal transduction pathway 
include soluble raf, mitogen-activated protein kinase kinase (MeK), erK, and the transcription factors elk-1 and c-Fos, a nuclear proto-oncogene that regulates expression 
of cyclin-dependent kinases (CdK).
Notes: 1) domains I and III are believed to be the primary ligand binding site. The “extended” or closed conformer of Her2 precludes ligand access; 2) the absence of the 
kinase domain (KD) on Her3 represents the impairment of this receptor; and 3) PI3K preferentially binds to phospho-Her3.International Journal of Women’s Health 2009:1 158
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for the receptor binding site because none has, as yet, been 
identified. Even though antibody-mediated blockade of 
receptor activation is believed to contribute to the antitumor 
effect, this is a gross oversimplification of the mechanisms 
(which remain ill-defined) by which trastuzumab induces 
tumor regression. Nonetheless, 2 mechanistic hypotheses 
have been proffered. The first involves perturbation of a 
number of signal transduction pathways following receptor 
endocytosis and proteolysis. As such, signaling through key 
molecules located “downstream” of the receptor, such as 
phosphatidylinositol 3 kinase (PI3K) and mitogen-activated 
protein kinase (MAPK), is disrupted.40 Furthermore, since 
ErbB receptors can be recycled to the cell membrane in a 
functional state, it is believed that trastuzumab enhances 
lysosomal breakdown of HER2 by recruiting a protein known 
as c-Cbl.41 This theory, however, has been challenged on the 
basis that surface downregulation is not an important mecha-
nism of drug action.42 Tumor cells treated with trastuzumab 
also exhibit growth arrest in G1 phase which is due, in part, to 
decreased amounts of proteins involved in the separation of 
p27kip1 and the cyclin E/cdk2 complex.43,44 Interestingly, it has 
also been reported that the antibody blocks angiogenesis by 
modulating the release of proangiogenic and antiangiogenic 
factors.45,46 Two other mechanisms that may contribute to 
antitumor activity include the ability to block DNA repair, 
an effect partially mediated by modulating p21WAF1 and 
formation of highly active truncated HER2 by inhibiting 
proteolytic cleavage of the extracellular domain (ECD).47,48 
While downregulation of HER2 is a plausible mechanism, 
several studies provide conflicting results suggesting that 
trastuzumab does not alter any of the previous findings, even 
the ability to cause apoptosis as the terminal event.42,49,50
An alternative, though not necessarily mutually exclu-
sive, explanation of the function of trastuzumab involves 
the recruitment of an immune component. Strong evidence 
suggests that the antibody binds and activates Fc recep-
tors expressed on immunocompetent lymphocytes and NK 
cells resulting in antibody-dependent cellular cytotoxicity 
(ADCC).51 Although persuasive, the phenomenon of ADCC 
may not be important, as inhibition of tumor growth has been 
observed with antibodies that lack the Fc fragment.52
Trastuzumab can be given in 2 different schedules. While 
most investigators used a 4  mg/kg loading dose followed by 
once weekly doses of 2 mg/kg, the results of other studies 
suggest an equally effective and more “patient-friendly” 
schedule of 6 mg/kg given every 3 weeks following an 
8 mg/kg loading dose. The latter schedule, based on the drug’s 
estimated half-life which ranges from 18 to 27 days, has also 
been shown to achieve steady-state blood concentrations 
(of 50–60 µg/mL), which is above the effective level of 
approximately 10 to 20 µg/mL.53
Lapatinib
Lapatinib, a small molecule that functions as a competitive 
inhibitor of both EGFR and HER2 tyrosine kinases, 
has been shown to cause prolonged downregulation of 
tyrosine phosphorylation in tumor cells.54 Because receptor 
phosphorylation induces recruitment and activation of 
numerous downstream effectors which ultimately control cell 
destiny, disruption of receptor-mediated signals can affect cell 
survival. One of the most important intermediaries affected is 
members of the Ras gene family (Figure 1). The Ras proteins 
are small guanosine triphosphate (GTP)-binding proteins 
that play principal roles in regulating cell proliferation.55 
Ras propagates signals emanating from the cell surface to 
the nucleus through dynamic interactions with other effector 
components. For example, binding of PI3K to Ras activates 
Akt, which enhances cell survival and stimulates new blood 
vessel formation.56,57 A number of other signaling effectors 
downstream of Ras include Raf gene family members, 
MAPK, ERK (extracellular signal-regulated kinase), 
and the transcription factors Elk-1 and c-Fos.58 However, 
because lapatinib’s inhibitory effect occurs at the level of the 
receptor, gene mutations or protein abnormalities of any of 
the intermediaries distal to the receptor are likely to confer 
resistance to lapatinib.
Lapatinib is administered orally at a dosage of 1250 mg 
daily.
Treatment-related toxicities
Safety data from clinical trials indicate that cardiac failure 
or decreases in left ventricular ejection fraction (LVEF) are 
the major toxicities associated with trastuzumab therapy.59,60 
Although the precise mechanism is not known, it has been 
postulated that contractile dysfunction may result from 
blocking a HER2 pathway that mediates growth and survival of 
cardiac smooth muscle cells.61–63 The most notable finding ema-
nated from the trastuzumab licensing trial involving patients 
with metastatic breast cancer.31 In this study, patients treated 
with first-line trastuzumab plus an anthracycline had a 16% 
risk of developing class III/IV (New York Heart Association) 
cardiotoxicity. Another study of patients (the majority of 
whom were exposed to anthracyclines) with advanced breast 
cancer treated with trastuzumab for a median of nearly two 
years reported an 11% incidence of grade III cardiac events.64 
Symptomatic or LVEF improvement occurred in nearly International Journal of Women’s Health 2009:1 159
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all patients following discontinuation of the antibody and 
institution of pharmacologic therapy for cardiac dysfunction. 
One of the major clinical anomalies is that the relatively high 
incidence of serious cardiac toxicity in these 2 studies has not 
been observed in other clinical trials of combined treatment 
with trastuzumab and an anthracycline.65–67
When used as monotherapy for metastatic breast cancer, 
cardiac toxicity develops in approximately 4.5% of patients 
who received prior anthracycline therapy.68 Cardiotoxic 
reactions, however, do not appear to be increased only with 
anthracyclines as these events have also been observed in 
studies of trastuzumab and paclitaxel.69–71 Although the 
incidence is approximately 4% when the two agents are 
given concurrently, the occurrence of cardiac toxicity is 1% 
with sequential administration of trastuzumab (ie, following 
completion of paclitaxel therapy). Collectively, these data 
suggest that: 1) the development of high-grade cardiac 
toxicity is more closely associated with the chemotherapeutic 
agents in the regimen71–73 (the seriousness of this toxic event 
has led to the conclusion that trastuzumab should not be given 
with anthracycline-containing regimens)74 and the schedule 
of trastuzumab administration; and 2) the myocardial damage 
can be partly attributed to the antibody itself. Nevertheless, 
outcomes data strongly suggest that combining trastuzumab 
with or following chemotherapy in the adjuvant setting results 
in benefits unparalleled by most available therapies for solid 
tumors. Addition of trastuzumab to chemotherapy should 
be strongly considered for patients with HER2–positive 
early-stage breast cancer, especially those at low risk for 
cardiovascular morbidity.
Interestingly, an extensive review of cardiac function 
in a large cohort of patients treated with lapatinib either 
as monotherapy or in combination with cytotoxic agents 
indicates that lapatinib does not appear to confer a high 
risk of developing heart failure.70 Of the 3558 patients, 
58 (1.6%) had confirmed decreases in LVEF. Furthermore, 
only 7 of the 58 patients (0.2%) were symptomatic. In addition, 
nearly all of the patients with decreased LVEF had medical 
or prior treatment histories that could have contributed to the 
cardiac event. Hence, even though signaling through HER2 is 
disrupted, lapatinib may be less cardiotoxic than trastuzumab. 
Part of the explanation may include the finding that lapatinib 
induces adenosine monophosphate kinase, which plays a key 
role in protecting cells against ischemic damage.75
HER trials
Results of early studies demonstrated that monotherapy 
trastuzumab was effective in patients with advanced breast 
cancer either as first-line therapy or in patients with disease 
progressing after chemotherapy.76,77 Because of the rela-
tively low response rates (ie, 25%) observed in patients 
participating in these studies, as well as preclinical evidence 
suggesting that the antibody may enhance the antitumor 
effect of chemotherapy,78 a number of clinical trials were 
performed to determine whether combining the two types 
of therapies were better than either alone. The most impor-
tant data were obtained in a pivotal phase III trial which 
showed that addition of trastuzumab to chemotherapy 
(doxorubicin plus cyclophosphamide or paclitaxel) resulted 
in superior outcomes compared to chemotherapy alone in 
all clinical endpoints (Table 1).31 In this study, women with 
HER2 overexpressing metastatic breast cancer who were 
randomized to trastuzumab plus chemotherapy achieved 
statistically significant improvement in overall response 
rates (ORR, 50% vs 32%; P  0.001), time to tumor progres-
sion (TTP, 9.1 vs 6.1 months; P  0.001), and overall survival 
(OS, 25.1 mo vs 20.3 mo; P  0.05). Importantly, more than 
half of the patients treated with chemotherapy alone received 
the antibody at the time of disease progression. Additional 
data confirming the efficacy of the paclitaxel-containing dou-
blet emanated from a phase II trial, which compared weekly 
administration of the taxane with or without trastuzumab.79 
Patients with HER2-positive tumors (scored as 2+ or 3+ by 
immunohistochemistry [IHC]) who received the combina-
tion, achieved significantly better ORR (84.5% vs 47.5%; 
P = 0.0005) and median TTP (369 days vs 272 days; P = 0.03). 
Both treatment arms were well tolerated; no cardiac events 
or grade 4 myelosuppression were observed. A consistent 
finding in both of these studies was the superior outcomes 
among patients with IHC 3+ tumors.
Because of the reported synergy between trastuzumab 
and docetaxel in preclinical models, a phase II trial evalu-
ated the combination of the 2 agents in patients with HER-2 
overexpressing metastatic breast cancer.80 Thirty subjects 
were treated with weekly doses of docetaxel and trastuzumab. 
One novel finding related to the presence, and correlation, 
of the extracellular domain (ECD) (of HER2) with response 
rate (RR). In patients with elevated HER2 serum ECD at 
baseline the RR was 76%; patients with low serum ECD 
levels had a RR of 33%.81 These findings were consistent 
with another study of trastuzumab plus docetaxel as first-
line treatment of HER2-positive metastatic breast cancer 
(Table 1).82 Compared to docetaxel alone, the combination 
was significantly more effective in all tumor endpoints includ-
ing ORR (61% vs 34%; P = 0.0002), median OS (31.2 vs 
22.7 months; P = 0.0325), median time to disease progression International Journal of Women’s Health 2009:1 160
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(11.7 vs 6.1 months; P = 0.0001), median time to treatment 
failure (9.8 vs 5.3 months; P = 0.0001), and median duration 
of response 11.7 vs 5.7 months; P = 0.009). Again, superior 
clinical outcomes correlated with tumors bearing gene-
amplification and/or oncoprotein overexpression. The most 
notable toxicities observed in patients who received both 
agents were the higher incidence of neutropenia and neutro-
penic fever and the death of 1 patient due to heart failure.
A phase III trial of paclitaxel with or without lapatinib, 
as first-line treatment for metastatic breast cancer has also 
been conducted.83 Interestingly, patients enrolled (n = 579) 
had tumors that were either HER2-negative or unknown at 
the time of study entry. Consistent with previous findings, 
no differences were observed in all endpoints regardless 
of treatment. However, among the 86 patients with HER2-
positive breast cancer, treatment with the combination 
resulted in significant improvements in TTP, event-free 
survival, ORR, and clinical benefit rate.
Having demonstrated that patients with advanced 
disease obtained significant benefit with trastuzumab, 
it was proposed that those with early stage HER2-positive 
breast cancer might also achieve substantial improve-
ment in clinical outcomes. To address this hypothesis, 
5 clinical trials were conducted to determine the relative 
importance of adding trastuzumab to standard adjuvant 
chemotherapy (Table 1).69,84,86,92 The HERA (Herceptin 
Adjuvant) Trial investigated the efficacy of trastuzumab 
(compared to observation only) when given after completion 
of loco-regional therapy and at least 4 cycles of adjuvant 
chemotherapy for 1 or 2 years.84 Trastuzumab was adminis-
tered every 3 weeks. The primary endpoint of the trial was 
disease-free survival (DFS), which was defined as any event 
including breast cancer recurrence, new second primary 
malignancy, or death. Thus far, analysis of only patients 
(n = 1694) randomized to the 1-year treatment arm (compared 
to control, n = 1693) has been reported. The initial publication 
(after a median follow-up of 1 year) indicated that DFS was 
significantly superior in patients who received trastuzumab 
(85.8% vs 77.4; P  0.0001). The absolute benefit of 8.4% 
corresponded to a 46% lower risk of developing an “event” 
(unadjusted hazard ratio [HR] of 0.54; 95% CI 0.43–0.67). 
This degree of benefit in early breast cancer represents the 
largest to be reported since the introduction of tamoxifen. 
At 2 years median follow-up, 59 and 90 patients have died 
in the trastuzumab and control groups, respectively. Analysis 
of these data showed a 34% reduction in risk of death with 
trastuzumab (HR 0.66, 95% CI 0.47–0.91; P = 0.0115) 
compared to the observation alone arm indicating a significant 
overall survival benefit.85 Similarly, the HR for the risk of a 
DFS event was 0.64 (95% CI 0.54–0.76; P  0.0001).
Two other phase III trials compared trastuzumab given con-
currently with, or following completion of, adjuvant chemo-
therapy in women with surgically resectable, HER2-postive 
(ie, 3+ by IHC or gene amplification detected by fluorescent 
in-situ hybridization [FISH]) breast cancer (Table 1). The 
combined results were reported in one publication.69 One, 
conducted by the National Surgical Adjuvant Breast and 
Bowel Project (NSABP B-31 trial), compared four 21-day 
cycles of doxorubicin and cyclophosphamide (AC) followed 
by four 21-day cycles of paclitaxel (T) (AC→T) to the same 
regimen plus 52 weekly doses of trastuzumab (H) beginning 
with the first paclitaxel dose (AC→TH); the other was North 
Central Cancer Treatment Group trial (NCCTG) N9831, 
which compared the same agents and same sequence (except 
T was given weekly for a total of 12 doses) and AC followed 
by concurrent administration of T plus trastuzumab, which 
was given weekly for 1 year. Similar to the HERA trial, the 
primary endpoint was DFS. At a median follow-up period of 
2 years, 261 events had occurred in the control arm compared 
to 133 in the trastuzumab-treated arm (HR 0.48, 95% CI 
0.39–0.59; P  0.0001). The absolute difference in percent-
age of patients alive and disease-free increased from 11.8% 
(at 3 years follow-up) to 18.2% (at 4 years follow-up) favoring 
the group receiving trastuzumab. In addition, the absolute 
difference in overall survival also favored the trastuzumab 
group, increasing from 2.6% to 4.8% (P = 0.015) at 3 years 
and 4 years follow-up, respectively. These highly significant 
differences crossed the a priori determined early stopping 
boundary and provided further evidence of the remarkable 
benefit attributable to trastuzumab.
Based on the positive outcomes as adjuvant therapy, 
it was hypothesized that pre-operative administration of 
trastuzumab plus chemotherapy could be beneficial in 
patients with HER-2 positive, locally advanced or inflam-
matory breast cancers. As such, neo-adjuvant therapy has 
the potential not only to render inoperable tumors resect-
able, but also lower rates of recurrence and cancer-related 
deaths in a group of patients who are almost certain to do 
poorly. Over the past 4 years, several groups have reported 
significantly higher pathologic complete responses (pCRs), 
an important predictor of superior DFS and OS in small 
numbers of patients who received trastuzumab as part of the 
treatment regimen (Table 1).87,88 These early findings were 
supported by results from a large phase III clinical trial that 
was presented recently.89 Compared to chemotherapy alone, 
patients who received chemotherapy plus trastuzumab have International Journal of Women’s Health 2009:1 165
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significantly higher pCR rates (20% vs 39%; P = 0.002) and 
event-free survival rates, 53% vs 70% (HR, 0.56; P = 0.006). 
Furthermore, in contrast to 1 of the early studies,86 the 
improved outcomes in this trial was observed in patients 
regardless of concomitant ER status.
The clinical activity and safety of lapatinib has also 
been investigated in patients with HER2-overexpressing 
or EGFR-positive advanced inflammatory breast cancers.90 
Objective responses were observed in 15 of the 30 women 
with HER2-positive disease; only 1 of the 15 patients with 
EGFR-positive/HER2-negative tumors achieved a clinical 
response. Notably, prior trastuzumab therapy did not influ-
ence response to lapatinib. Although not currently approved 
for use in this setting, it is likely that trastuzumab will receive 
FDA approval as part of neo-adjuvant therapy in the near 
future.
Nonetheless, the concern for cardiac toxicity in patients 
receiving trastuzumab plus chemotherapy (especially anthra-
cyclines) has pushed investigators to find alternative treat-
ment regimens with equal efficacy and better tolerability. 
Based on promising preclinical data combining carboplatin 
with paclitaxel, a phase III study was performed to evaluate 
the efficacy and safety of trastuzumab plus paclitaxel with 
our without carboplatin.91 As front-line therapy for advanced 
breast cancer, patients randomized to the 3-drug regimen had 
significantly better ORR (52% vs 36%; P = 0.04) and median 
progression-free survival (10.7 vs 7.1 months; P = 0.03). The 
only serious toxicity that occurred more frequently with the 
triple drug regimen was grade 4 neutropenia.
While the taxanes and anthracyclines are among the 
most effective agents used in the treatment of breast cancer, 
combinations of trastuzumab with other agents such as 
vinorelbine,93 gemcitabine,94 and capecitabine95 have also 
been reported to be quite active.
Despite clinical confirmation that HER2 is an important 
tumor target and that selective targeting can be achieved, there 
are several realities that must be emphasized. First, in spite of 
early benefit, tumor progression occurs in virtually all patients 
with advanced disease and in a significant number of patients 
with early breast cancer; 31,69,84 second, only modestly active 
as single agents, tumor outcomes are significantly improved 
when either agent is combined with chemotherapy; and third, 
although relatively well tolerated, cardiotoxicity is associated 
with HER2-targeted agents.72
Based on the results of phase III clinical trial, lapatinib 
provides some measure of hope for patients with tumors 
progressing on trastuzumab and chemotherapy.72 Originally 
designed to include 528 women, enrollment was terminated 
and data locked following an interim analysis of efficacy and 
safety data by an independent monitoring committee. At that 
time, 324 patients had been randomized to capecitabine plus 
lapatinib or capecitabine alone. On the basis of 121 events, 
49 in the combination and 72 in the monotherapy groups, 
a 51% improvement in TTP (8.4 months and 4.4 months; 
P  0.001) favored the group receiving capecitabine and 
lapatinib. A secondary endpoint, progression-free survival, 
defined as the time from randomization to disease progres-
sion or death from any cause, was also improved in the 
combination-therapy group (HR 0.47; 95% CI 0.33–0.67; 
P  0.001). In addition, central nervous system involvement 
was significantly lower with combination therapy compared to 
capecitabine alone, 2% versus 11%, respectively, P = 0.0445. 
The latter finding is of immense interest because the develop-
ment of brain metastases occurs in approximately one-third of 
patients with advanced HER2-positive breast cancer. A small 
phase II study was conducted in women to evaluate the effect 
of lapatinib on progressive brain metastases despite prior 
radiation therapy.96 Among 39 subjects who were previously 
treated with trastuzumab, a PR was achieved in one patient; 
further progression was not observed in seven other patients 
16 weeks after beginning lapatinib.
Further information related to completed and ongoing 
clinical trials of both agents can be accessed at: http://www.
cancer.gov/cancertopics/druginfo/trastuzumab and http://
www.cancer.gov/cancertopics/druginfo/lapatinibditosylate.
HER secrets
A number of interesting findings suggest that HER2 may 
be the most intriguing member of the ErbB family.16,17 Of 
note, at least 7 EGF-like molecules have been shown to bind 
EGFR, HER3 and HER4; none, however, binds to HER2. 
The reason why identification of a stimulating ligand remains 
elusive could be related to HER2 itself. Analysis of the 
crystal structure exposed a pair of clarifying facets about the 
receptor: 1) the extended conformation of monomeric HER2 
may hinder binding of any EGF-like peptide (Figure 1);97 and 
2) structural defects at the receptor binding site appear to be 
the result of unconserved or altered amino acid residues.99
While ligand binding triggers receptor dimerization, the 
absence of specific stimulatory molecules does not preclude 
kinase activation. Indeed, overexpression of HER2 results 
in formation of receptor homodimers that are constitutively 
active.99 Furthermore, a cursory glance at the intracellular 
signaling cascade could result in the erroneous conclusion 
that activated HER2 only has a rudimentary role in trafficking 
signals down a vertical transduction pathway (Figure 1). International Journal of Women’s Health 2009:1 166
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Signaling, however, is phenomenally diverse and complex, 
in large part, because HER2 is believed to be the preferred 
dimeric partner of the other ErbB family members.100 This 
feature has profound implications. For example, the dimeric 
partner and its activating ligand play essential roles in deter-
mining not only which receptor sites are phosphorylated, but 
also which downstream proteins are recruited.101 The result is 
an expansion of the signaling repertoire. Moreover, formation 
of HER2 heterodimers may be of pathologic importance. 
This conclusion is supported by the surprising finding that 
although neither monomeric HER2 (ligand-less) nor HER3 
(kinase-impaired) can support linear signaling alone, the 
combination appears to possess the most potent mitogenic 
properties.102 Similarly, tumorigenic signals emanating from 
the EGFR/HER2 heterodimer are stronger compared to either 
homodimer alone.103 These bi-partisan relationships may 
also be clinically relevant as the poor prognosis associated 
with tumors overexpressing HER2 could be partly due to 
transactivation of the receptor’s intrinsically high tyrosine 
kinase activity by the consorting partner. Reports of patient 
tumors continuing to respond to trastuzumab even after ini-
tial disease progression104–107 further suggest that part of the 
HER2 mystique may be related to another member of the 
HER family. Additional evidence to support this conclusion 
is provided by preclinical models. Analysis of mice bear-
ing a breast cancer xenograft that co-expresses EGFR and 
HER2 revealed the formation of EGFR and full-length HER2 
(p185ErbB2) heterodimers.108 More important, phosphoryla-
tion of 2 key downstream proteins was inhibited only when 
both receptor kinases were blocked. This finding provides a 
possible explanation for the efficacy of lapatinib in tumors 
where trastuzumab had little effect.
Molecularly, the importance of HER2 extends even 
further as the full-length protein (p185ErbB2) undergoes 
proteolytic truncation resulting in a deceptively shortened 
receptor (p95ErbB2) with increased autokinase activity.109 
Clinically, elevated serum levels of the dissociated ECD 
have been correlated with poorer responses to therapy 
(which contrasts with another report)81 as well as lymph node 
metastasis.110,111 The presence of cleaved HER2 is notable for 
2 other reasons. First, the truncated receptor preferentially 
dimerizes with HER3,108 and second, phosphorylation of 
p95ErbB2 can be blocked by lapatinib but not trastuzumab.108 
Thus, the heterodimer concept could explain the effectiveness 
of lapatinib in patients who fail trastuzumab. Intriguingly, 
the answer may be partly related to EGFR. While formation 
of antibody–receptor complexes is believed to undergo 
endocytosis and subsequent proteolytic degradation, specific 
inhibition of the EGFR tyrosine kinase have been shown, both 
ex vivo and in vivo, to affect heterodimer formation resulting 
in marked impairment of HER2 signaling.112–114
The importance of HER2 heterodimers in normal 
developmental processes also provides a clue to explain 
one of the major toxicities associated with anti-HER2 
therapy. Based on the biological abnormalities of 
HER2 and HER3, it is now known that a family of EGF-
like glycoproteins known as the heregulins (HRG) can 
overcome the limitations of each receptor. Although HRGs 
bind to HER3 and HER4, one of the active complexes 
through which HRG signaling occurs is the HER2/HER3 
heterodimer.102 The relevance of this finding has been 
observed in preclinical models, which demonstrate the 
critical role of HER2 and HER3 in development and 
differentiation of cardiac myocytes.115 Knockout of the 
HRG and HER2 genes resulted in thinning of the ventricu-
lar wall and complete absence of myocyte trabeculation, 
which led to cardiac hypertrophy, dysrhythmias, and vascu-
lar rarefaction. Embryonic viability ceased by day 11. The 
relative importance of HER3 was also demonstrated using 
HER3–/– (ie, knockout) mouse embryos, which resulted in 
significant valvular defects. So severely underdeveloped, 
the valves were unable to support normal cardiac func-
tion causing mitral and aortic regurgitation.116 Thus, the 
pathogenic mechanism of trastuzumab-associated myo-
cardial dysfunction could be partly related to inhibition 
of signaling through HER2 or blocking HER2-mediated 
transactivation of HER3.
HER2 may be at the focus of yet another malevolent 
relationship, one that involves the ER. Although the 
connection could be a manifestation of genetic evolution, 
it is more likely to be one that has been genetically conserved 
since growth factor pathways have been demonstrated 
to influence, and be influenced by, ERα signaling.117 
Compelling evidence suggest that estrogen deprivation 
strategies are associated with overexpression of heregulin,118 
as well as HER1 and HER2, which may contribute to the 
development of resistance to endocrine therapies in breast 
cancer.119,120 Preliminary results of an important clinical 
trial to test this hypothesis have been recently reported.121 
Eligibility was based on confirmation of positive hormone 
receptor disease regardless of HER2 status. Of the nearly 
1300 patients enrolled, 219 of them had tumors that were 
HER2-positive also. In patients with double receptor-
positive tumors, addition of lapatinib to letrozole improved 
the RR (from 15% to 28%) and progression-free survival 
(from 3 months to 8.2 months). No differences in endpoints International Journal of Women’s Health 2009:1 167
Long-term experience targeting Her2 Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
were observed between treatment groups in patients with 
HER2-negative tumors.
Finally, mortality from breast cancer will be even lower 
if the disease could be prevented or were altogether less 
common. Three clinical studies, each based on the association 
between estrogens and breast cancer, have demonstrated that 
chemoprevention can reduce the risk of developing invasive 
breast cancer in patients at high-risk for the disease.122–124 
Despite the efficacy of tamoxifen and raloxifene, neither 
agent reduces the occurrence of ER-negative tumors. Tethered 
to this finding is another possible outcome, one that is truly 
hypothetical, though within the realm of reality. Because 
laboratory studies have shown that estrogen deprivation 
upregulates the HER2 signaling pathway, one concern relates 
to the possible development of HER2-postive breast cancer 
due to widespread application of chemopreventive therapy. 
Part of the answer may indirectly be provided by a phase III 
trial (EGF30008) involving patients with ER-positive breast 
cancer who are randomized to receive an aromatase inhibitor 
with or without a HER2 antagonist.
HER destiny
Despite the voluminous amount of new information that has 
been published, it is humbling to note that besides being a 
valid target, only a small portion of the receptor’s complete 
biology is apparently known. The lack of full understanding 
underlies our inability to explain why anti-HER2 therapy is 
not effective in all tumors that overexpress the receptor or why 
continuation of the antibody is beneficial in some patients 
who progressed on a trastuzumab-containing regimen. 
Because cancer investigations have provided convincing 
evidence that multiple signaling defects exist in most solid 
tumors, including breast cancer, it would be reasonable to 
suggest that dual- or multikinase inhibitors will be more 
efficient at eradicating HER2-positive tumor cells. Still, 
it remains unclear whether lapatinib (or any other multi-
kinase inhibitor) will be more effective than trastuzumab. It is 
highly probable that one agent will be active in some tumors 
that are resistant to another agent. At the same time, there is an 
opportunity to assess whether combined therapy (ie, targeting 
HER2 from the “outside” and “inside” simultaneously) is 
significantly better than either type of agent alone. Prelimi-
nary results of 1 such study have been reported.125
What is certain is that tumor resistance will develop. 
This last conclusion is supported by the observation that 
nearly all patients with HER2-positive metastatic breast 
cancer appear to become refractory within 12 months after 
initially responding to trastuzumab.104 The finding that most 
of the patients (with tumors resistant to trastuzumab) exhibit 
disease progression after 6 months of treatment with lapa-
tinib suggests that resistance also develops against small-
molecule inhibitors. Even when used in the adjuvant setting, 
disease relapse has occurred following antibody therapy.69,84 
As such, research must be directed toward understanding the 
molecular and biochemical mechanisms of tumor resistance. 
Elucidating these mechanisms would be beneficial in 2 ways: 
1) the development of effective alternative agents and 2) the 
introduction of strategies that could prevent (or at least delay) 
the emergence of drug-resistant tumor cells. The former is 
already underway. One of the most promising new agents 
is pertuzumab (OmnitargTM), a drug that binds to a critical 
region on the ectodomain of HER2 thereby interfering with 
the receptor’s ability to dimerize. Phase I trials have shown 
pertuzumab to be tolerable and active.126 Preliminary results 
of a phase II study indicate significant activity in patients who 
progressed on trastuzumab.127 Of the 33 patients enrolled, 
1 complete response, 5 partial responses, and 17 stable 
disease were achieved. Preclinical studies suggest that pertu-
zumab can even inhibit growth of tumor cells with low-level 
expression of HER2.128
What have also been elucidated are the many pathways 
(and hence targets) downstream, or completely indepen-
dent, of HER2 that may be linked to the aberrant behavior 
of HER2-positive tumor cells. Mutations involving PI3K, 
Akt, and mTOR (mammalian target of rapamycin) may 
result in constitutive activation of these effectors as well as 
tumor resistance. As such, new inhibitors such as LY294002 
(a quercetin derivative), perifosine (Keryx Pharmaceuticals), 
and everolimus (Novartis Pharmaceuticals), which have been 
tested in preclinical models, may have a role in the treat-
ment of patients with HER2-positive disease. In addition, 
insulin-like growth factor-1 (IGF-1) also appears to be an 
important co-receptor with the unique ability to induce HER2 
phosphorylation.129 Thus, targeted inhibition of insulin-like 
growth factor-1 may be beneficial in patients with HER2 
overexpressing breast cancer. Other types of therapies that are 
currently being investigated include inhibitors of heat-shock 
protein 90 and histone deacetylase, irreversible inhibitors 
of the HER2 kinase, combinations of HER2 inhibitors and 
antiangiogenic agents, and chemotherapy conjugated to an 
antibody.
Despite the plethora of publications related to HER2, the 
extent of what is not known remains uncertain. The reality 
is that HER2 is an extraordinarily dynamic structure, whose 
genome will likely be altered by mutational and epigenetic 
events. Nonetheless, it is highly conceivable that scientists International Journal of Women’s Health 2009:1 168
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will one day unravel the complex mysteries of tumor cell 
signaling, may be even HER, too.
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